nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.0557	0.0557	CcSEcCtD
Methsuximide—Proteinuria—Vandetanib—thyroid cancer	0.0552	0.0552	CcSEcCtD
Methsuximide—Protein urine present—Vandetanib—thyroid cancer	0.0545	0.0545	CcSEcCtD
Methsuximide—Proteinuria—Sorafenib—thyroid cancer	0.0372	0.0372	CcSEcCtD
Methsuximide—Protein urine present—Sorafenib—thyroid cancer	0.0367	0.0367	CcSEcCtD
Methsuximide—Weight decreased—Vandetanib—thyroid cancer	0.0275	0.0275	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.0269	0.0269	CcSEcCtD
Methsuximide—Haematuria—Vandetanib—thyroid cancer	0.0259	0.0259	CcSEcCtD
Methsuximide—Erythema multiforme—Vandetanib—thyroid cancer	0.023	0.023	CcSEcCtD
Methsuximide—Vision blurred—Vandetanib—thyroid cancer	0.02	0.02	CcSEcCtD
Methsuximide—Weight decreased—Sorafenib—thyroid cancer	0.0186	0.0186	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.0181	0.0181	CcSEcCtD
Methsuximide—Insomnia—Vandetanib—thyroid cancer	0.0157	0.0157	CcSEcCtD
Methsuximide—Erythema multiforme—Sorafenib—thyroid cancer	0.0155	0.0155	CcSEcCtD
Methsuximide—Decreased appetite—Vandetanib—thyroid cancer	0.015	0.015	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0149	0.0149	CcSEcCtD
Methsuximide—Constipation—Vandetanib—thyroid cancer	0.0148	0.0148	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0142	0.0142	CcSEcCtD
Methsuximide—Abdominal pain—Vandetanib—thyroid cancer	0.0137	0.0137	CcSEcCtD
Methsuximide—Leukopenia—Sorafenib—thyroid cancer	0.0128	0.0128	CcSEcCtD
Methsuximide—Hiccups—Epirubicin—thyroid cancer	0.0121	0.0121	CcSEcCtD
Methsuximide—Diarrhoea—Vandetanib—thyroid cancer	0.0118	0.0118	CcSEcCtD
Methsuximide—Dizziness—Vandetanib—thyroid cancer	0.0114	0.0114	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—thyroid cancer	0.0112	0.0112	CcSEcCtD
Methsuximide—Anorexia—Sorafenib—thyroid cancer	0.0111	0.0111	CcSEcCtD
Methsuximide—Vomiting—Vandetanib—thyroid cancer	0.011	0.011	CcSEcCtD
Methsuximide—Rash—Vandetanib—thyroid cancer	0.0109	0.0109	CcSEcCtD
Methsuximide—Dermatitis—Vandetanib—thyroid cancer	0.0109	0.0109	CcSEcCtD
Methsuximide—Headache—Vandetanib—thyroid cancer	0.0108	0.0108	CcSEcCtD
Methsuximide—Nausea—Vandetanib—thyroid cancer	0.0103	0.0103	CcSEcCtD
Methsuximide—Decreased appetite—Sorafenib—thyroid cancer	0.0101	0.0101	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0101	0.0101	CcSEcCtD
Methsuximide—Constipation—Sorafenib—thyroid cancer	0.00998	0.00998	CcSEcCtD
Methsuximide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00955	0.00955	CcSEcCtD
Methsuximide—Urticaria—Sorafenib—thyroid cancer	0.00928	0.00928	CcSEcCtD
Methsuximide—Abdominal pain—Sorafenib—thyroid cancer	0.00923	0.00923	CcSEcCtD
Methsuximide—Ataxia—Epirubicin—thyroid cancer	0.00826	0.00826	CcSEcCtD
Methsuximide—Diarrhoea—Sorafenib—thyroid cancer	0.00799	0.00799	CcSEcCtD
Methsuximide—Dizziness—Sorafenib—thyroid cancer	0.00772	0.00772	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—thyroid cancer	0.00764	0.00764	CcSEcCtD
Methsuximide—Eosinophilia—Epirubicin—thyroid cancer	0.00751	0.00751	CcSEcCtD
Methsuximide—Vomiting—Sorafenib—thyroid cancer	0.00742	0.00742	CcSEcCtD
Methsuximide—Rash—Sorafenib—thyroid cancer	0.00736	0.00736	CcSEcCtD
Methsuximide—Dermatitis—Sorafenib—thyroid cancer	0.00736	0.00736	CcSEcCtD
Methsuximide—Headache—Sorafenib—thyroid cancer	0.00731	0.00731	CcSEcCtD
Methsuximide—Pancytopenia—Epirubicin—thyroid cancer	0.00721	0.00721	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—thyroid cancer	0.00695	0.00695	CcSEcCtD
Methsuximide—Nausea—Sorafenib—thyroid cancer	0.00694	0.00694	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—thyroid cancer	0.00686	0.00686	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—thyroid cancer	0.00677	0.00677	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00671	0.00671	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—thyroid cancer	0.00667	0.00667	CcSEcCtD
Methsuximide—Haematuria—Epirubicin—thyroid cancer	0.00645	0.00645	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—thyroid cancer	0.00635	0.00635	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—thyroid cancer	0.00626	0.00626	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00621	0.00621	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—thyroid cancer	0.00597	0.00597	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—thyroid cancer	0.00574	0.00574	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—thyroid cancer	0.00531	0.00531	CcSEcCtD
Methsuximide—Tension—Epirubicin—thyroid cancer	0.00519	0.00519	CcSEcCtD
Methsuximide—Nervousness—Epirubicin—thyroid cancer	0.00514	0.00514	CcSEcCtD
Methsuximide—Vision blurred—Epirubicin—thyroid cancer	0.00498	0.00498	CcSEcCtD
Methsuximide—Tension—Doxorubicin—thyroid cancer	0.0048	0.0048	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—thyroid cancer	0.00475	0.00475	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—thyroid cancer	0.00473	0.00473	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—thyroid cancer	0.00461	0.00461	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—thyroid cancer	0.00438	0.00438	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—thyroid cancer	0.00435	0.00435	CcSEcCtD
Methsuximide—Anorexia—Epirubicin—thyroid cancer	0.00411	0.00411	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—thyroid cancer	0.00403	0.00403	CcSEcCtD
Methsuximide—Insomnia—Epirubicin—thyroid cancer	0.0039	0.0039	CcSEcCtD
Methsuximide—Somnolence—Epirubicin—thyroid cancer	0.00384	0.00384	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—thyroid cancer	0.00381	0.00381	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—thyroid cancer	0.00375	0.00375	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00373	0.00373	CcSEcCtD
Methsuximide—Constipation—Epirubicin—thyroid cancer	0.00369	0.00369	CcSEcCtD
Methsuximide—Insomnia—Doxorubicin—thyroid cancer	0.00361	0.00361	CcSEcCtD
Methsuximide—Feeling abnormal—Epirubicin—thyroid cancer	0.00356	0.00356	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—thyroid cancer	0.00355	0.00355	CcSEcCtD
Methsuximide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—thyroid cancer	0.00347	0.00347	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00345	0.00345	CcSEcCtD
Methsuximide—Urticaria—Epirubicin—thyroid cancer	0.00343	0.00343	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—thyroid cancer	0.00341	0.00341	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—thyroid cancer	0.00341	0.00341	CcSEcCtD
Methsuximide—Feeling abnormal—Doxorubicin—thyroid cancer	0.00329	0.00329	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00326	0.00326	CcSEcCtD
Methsuximide—Urticaria—Doxorubicin—thyroid cancer	0.00317	0.00317	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—thyroid cancer	0.00316	0.00316	CcSEcCtD
Methsuximide—Diarrhoea—Epirubicin—thyroid cancer	0.00295	0.00295	CcSEcCtD
Methsuximide—Dizziness—Epirubicin—thyroid cancer	0.00285	0.00285	CcSEcCtD
Methsuximide—Vomiting—Epirubicin—thyroid cancer	0.00274	0.00274	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—thyroid cancer	0.00273	0.00273	CcSEcCtD
Methsuximide—Rash—Epirubicin—thyroid cancer	0.00272	0.00272	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—thyroid cancer	0.00272	0.00272	CcSEcCtD
Methsuximide—Headache—Epirubicin—thyroid cancer	0.0027	0.0027	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—thyroid cancer	0.00264	0.00264	CcSEcCtD
Methsuximide—Nausea—Epirubicin—thyroid cancer	0.00256	0.00256	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Methsuximide—Rash—Doxorubicin—thyroid cancer	0.00252	0.00252	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—thyroid cancer	0.00252	0.00252	CcSEcCtD
Methsuximide—Headache—Doxorubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Methsuximide—Nausea—Doxorubicin—thyroid cancer	0.00237	0.00237	CcSEcCtD
